Why the study?
Do combinations of QTc-prolonging drugs result in additive QTc prolongation?
Do combinations of QTc-prolonging drugs result in additive QTc prolongation?
The risk of additive QTc prolongation from drug combinations is not uniform and depends on specific drug interactions and exposure, highlighting the utility of the AZCERT classification for risk prediction.
These observations indicate that indiscriminate combinations of QTc-prolonging drugs do not necessarily result in additive QTc prolongation and suggest that QT prolongation caused by drug combinations strongly depends on the nature of the combination partners and individual drug exposure. Concurrently, it stresses the value of the AZCERT classification also for the risk prediction of combination therapies with QT-prolonging drugs.
No takes yet. Share an insight, caveat, or question.
Meid et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: